Last update 23 Jan 2025
Guangzhou Shunjian Biomedical Technology Co., Ltd.

Guangzhou Shunjian Biomedical Technology Co., Ltd.

Private Company|
2012|
Guangdong Sheng, China

Overview

Tags

Urogenital Diseases
Neoplasms
Digestive System Disorders
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Immune System Diseases2
Endocrinology and Metabolic Disease1
Hemic and Lymphatic Diseases1
Infectious Diseases1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
XIAP x cIAP1/cIAP21
Bcr-Abl T315I x c-Kit1

Related

3
Drugs associated with Guangzhou Shunjian Biomedical Technology Co., Ltd.
Olverembatinib
Target
Bcr-Abl T315I x c-Kit
Mechanism
Bcr-Abl T315I inhibitors [+1]
Active Org.
Ascentage Pharma Group, Inc. [+3]
Originator Org.
Guangzhou Shunjian Biomedical Technology Co., Ltd.Guangzhou Shunjian Biomedical Technology Co., Ltd.
Active Indication
Aggressive-Phase Chronic Myelocytic Leukemia [+11]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
CN
First Approval Date24 Nov 2021
Dasminapant
Target
XIAP x cIAP1/cIAP2
Mechanism
XIAP inhibitors [+1]
Active Org.
Guangzhou Shunjian Biomedical Technology Co., Ltd.Guangzhou Shunjian Biomedical Technology Co., Ltd. [+3]
Originator Org.
Jiangsu Yasheng Pharmaceutical Development Co. Ltd.Jiangsu Yasheng Pharmaceutical Development Co. Ltd.
Active Indication
Pancreatic Ductal Adenocarcinoma [+4]
Inactive Indication
Colorectal Cancer [+2]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
HQP8361
Target
MST1R x c-Met
Mechanism
MST1R inhibitors [+1]
Active Org.
Merck & Co., Inc.Merck & Co., Inc. [+1]
Originator Org.
Merck & Co., Inc.Merck & Co., Inc.
Active Indication
Neoplasms
Inactive Indication
Advanced cancer [+1]
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
14
Clinical Trials associated with Guangzhou Shunjian Biomedical Technology Co., Ltd.
CTR20243842
/ RecruitingPhase 3
奥雷巴替尼治疗SDH缺陷型胃肠道间质瘤的单臂关键性注册Ⅲ期临床研究（POLARIS-3）
[Translation] A single-arm pivotal registration phase III clinical study of orebactinib in the treatment of SDH-deficient gastrointestinal stromal tumors (POLARIS-3)
CTR20232680
/ RecruitingPhase 3
奥雷巴替尼联合化疗对比伊马替尼联合化疗治疗新诊断Ph染色体阳性的急性淋巴细胞白血病（Ph+ALL）患者的关键注册性III期临床研究
[Translation] A pivotal registration phase III study of ogrebatinib plus chemotherapy versus imatinib plus chemotherapy in patients with newly diagnosed Ph+ ALL
CTR20230522
/ RecruitingPhase 1
APG-5918治疗贫血的安全性、药代动力学和有效性的Ⅰ期临床研究
[Translation] Phase I clinical study on the safety, pharmacokinetics and efficacy of APG-5918 in the treatment of anemia
100 Clinical Results associated with Guangzhou Shunjian Biomedical Technology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Guangzhou Shunjian Biomedical Technology Co., Ltd.
Login to view more data
100 Deals associated with Guangzhou Shunjian Biomedical Technology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Guangzhou Shunjian Biomedical Technology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
1
Approved
Other
1
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free